Thermo Fisher Scientific TMO is set to release third-quarter 2026 results on Oct. 21, before the market opens.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $6.03, which surpassed the Zacks Consensus Estimate by 5.60%. The company’s earnings topped estimates in each of the trailing four quarters, the average surprise being 4.42%.
Q3 Estimates for TMO
The Zacks Consensus Estimate for revenues is pegged at $11.91 billion, indicating an increase of 7.1% from the year-ago reported figure.
The consensus mark for the company’s EPS implies a 10.5% year-over-year rise to $6.40. The estimate has remained unchanged in the past 30 days.
Factors Likely to Influence TMO’s Q3 Results
Life Sciences Solutions
The segment’s performance is expected to have benefited from continued strength in the Bioproduction business.
A steady cadence of product launches is also expected to have supported the Life Sciences Solutions segment. Among its newer innovations, Thermo Fisher introduced the Gibco CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to support strong cell growth and protein production across CHO-K1 cell lines.
The company also launched the Multiskan Ease Absorbance Microplate Reader to support protein quantification, enzyme-linked immunosorbent assays (ELISAs), cell viability studies, microbial growth monitoring and other routine laboratory applications with simplified operation and dependable performance. Thermo Fisher’s new Applied Biosystems PowerFlex Thermal Cycler is designed to help deliver enhanced flexibility, precise thermal performance and improved productivity for modern molecular biology laboratories. We expect all these developments to have positively boosted revenues in the third quarter of 2026.
Per the Zacks Consensus Estimate, the Life Sciences Solutions revenues are expected to increase 10.1% year over year.
Analytical Instruments
The segment is likely to have witnessed growth across all three businesses, led by the electron microscopy business in third-quarter 2026.
Also, Thermo Fisher’s strength in innovations may have remained a bright spot. The company introduced the EMPAD G2 detector to help researchers capture more information about materials in a single scan, recording both the strongest and weakest signals without sacrificing imaging speed or data quality.
TMO also introduced Orbitrap Isora Mass Spectrometer and Orbitrap Isora Pro Mass Spectrometer, the company’s first Orbitrap instruments with a dedicated isotope ratio analysis mode. In the previous quarter, Thermo Fisher collaborated with NVIDIA, which is expected to have made further progress toward commercializing AI-enabled scientific workflow solutions. These developments might have favorably boosted the company’s top line in the third quarter.
Per the Zacks Consensus Estimate, revenues in this segment are projected to increase 2.6% year over year.
Specialty Diagnostics
Similar to the previous quarter, the segment’s growth may have been driven by the immunodiagnostics and transplant diagnostics businesses. The healthcare market channel likely contributed to third-quarter revenues.
Recent product innovations are also expected to have supported the segment's performance. These include InstaFlux, an integrated media-on-demand enrichment workflow that helps food microbiology laboratories simplify media preparation, improve productivity and enhance sample traceability, as well as Thermo Scientific Brilliance Candida 2 Agar and Spectra Candida Agar, new color-based (chromogenic) culture media to quickly detect and differentiate clinically important Candida species.
Thermo Fisher Scientific Inc. Price and EPS Surprise
Thermo Fisher Scientific Inc. price-eps-surprise | Thermo Fisher Scientific Inc. Quote
Thermo Fisher marked a notable development in August 2026, completing the sale of its microbiology business to Astorg for approximately $1.075 billion.
The Zacks Consensus Estimate for Specialty Diagnostics revenues implies a decline of 3% year over year.
Laboratory Products and Biopharma Services
In the third quarter of 2026, the segment is likely to have delivered solid performance due to its clinical research business and the research and safety market channel.
Thermo Fisher launched the PPD CorEvitas Vitiligo Registry, a prospective, observational clinical registry designed to generate longitudinal real-world evidence in adolescents and adults living with nonsegmental vitiligo (NSV). During the previous quarter, Thermo Fisher’s PPD clinical research business expanded its global bioanalytical capabilities by opening a new bioanalytical and biomarker laboratory in Gothenburg, Sweden. Collectively, these developments are expected to have supported the segment's third-quarter revenues.
The Zacks Consensus Estimate for revenues indicates an increase of 9.8% year over year.
What Our Model Unveils for TMO
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see below.
Earnings ESP: Thermo Fisher has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
You can see the complete list of today’s Zacks #1 Rank stocks here.
MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
TG Therapeutics TGTX has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon.
TGTX’s earnings beat estimates in one of the trailing four quarters and missed on the remaining three occasions, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter’s figure.
Revvity RVTY has an Earnings ESP of +1.03% and a Zacks Rank #2 at present. The company is slated to release third-quarter 2026 results on Nov. 3.
RVTY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter’s figure.
HeartSciences HSCS has an Earnings ESP of +2.70% and a Zacks Rank #2 at present. The company is expected to release second-quarter fiscal 2027 results soon.
HSCS’ earnings surpassed estimates in two of the trailing four quarters and missed in the other two, the average negative surprise being 0.06%. The Zacks Consensus Estimate for fiscal second-quarter loss per share calls for an improvement of 12.9% from the year-ago quarter’s figure.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report
TG Therapeutics, Inc. (TGTX): Free Stock Analysis Report
HeartSciences Inc. (HSCS): Free Stock Analysis Report
Revvity Inc. (RVTY): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).